Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Cellular

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44338   clinical trials with a EudraCT protocol, of which   7368   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    680 result(s) found for: Cellular. Displaying page 1 of 34.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2008-004489-23 Sponsor Protocol Number: NVI-248 Start Date*: 2008-10-20
    Sponsor Name:Netherlands Vaccine Institute
    Full Title: Development of cellular immune response after infant pneumococcal conjugate vaccinations
    Medical condition: Cellular immune response(long term memory) after following the infant immunisation programme with a pneumococcal conjugate vaccine (Prevenar).
    Disease:
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2012-004486-41 Sponsor Protocol Number: 20130401 Start Date*: 2013-01-29
    Sponsor Name:Karolinska University Hospital, Huddinge, Sweden
    Full Title: Vaccination of antibody deficient patients with Prevenar13 - a comparative study between antibody response and cellular immunity.
    Medical condition: Patients with IgG-deficiency
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-003456-13 Sponsor Protocol Number: DEN-313 Start Date*: 2022-12-21
    Sponsor Name:Takeda Vaccines, Inc.
    Full Title: An Open Label, Phase 2 Study to Investigate Cell-mediated Immunity and Safety of a Tetravalent Dengue Vaccine Candidate (TDV) Administered Subcutaneously in Healthy Children Aged 4 to 16 Years
    Medical condition: Dengue fever
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10012312 Dengue fever virus infection LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2021-002014-14 Sponsor Protocol Number: COV-PBO-MO28 Start Date*: 2021-04-20
    Sponsor Name:Fakultní nemocnice Hradec Králové
    Full Title: Antibody and cellular response 28 days after the first dose of COVID-19 vaccine (Moderna) and then 33 weeks after the second dose and 8-12 weeks after the third dose in clinically stable patients w...
    Medical condition: Antibody and cellular response 28 days after the first dose of COVID-19 vaccine (Moderna) and then 33 weeks after the second dose and 8-12 weeks after the third dose in clinically stable patients w...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-020450-33 Sponsor Protocol Number: IX-senesc2.0 Start Date*: 2010-06-23
    Sponsor Name:Institute of Specific Prophylaxis and Tropical Medicine
    Full Title: Characterization of cellular and humoral immunity in the elderly upon vaccination with the purified inactivated Japanese Encephalitis Vaccine IXIARO®
    Medical condition: The aim of this project is to investigate humoral and cellular immune responses before and after immunisation with the Japanese encephalitis vaccine IXIARO in subjects above 65 years of age in comp...
    Disease: Version SOC Term Classification Code Term Level
    14.0 10042613 - Surgical and medical procedures 10069544 Japanese encephalitis immunization LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2008-005800-24 Sponsor Protocol Number: version1.0 Start Date*: 2008-10-22
    Sponsor Name:Medizinische Universität Wien, Institut für Spezifische Prophylaxe und Tropenmedizin
    Full Title: Characterisation of humoral and cellular immunity of low- and high-responder after TBE vaccination
    Medical condition: The aim of this project is to investigate the humoral and cellular immune responses of low-responders after TBE vaccination in order to find parameters regarding immunoregulation against TBE. It is...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039244 Routine vaccination LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2015-001259-63 Sponsor Protocol Number: Pollenvaccine2014-01-15 Start Date*: 2016-03-09
    Sponsor Name:Department of Clinical Science, Intervention and Technology, Karolinska Institute
    Full Title: Intralymphatic immunotherapy in increasing doses up to 10 000 SQ-U -a human randomized clinical trial
    Medical condition: Patients with severe to moderate Allegic rhinitis.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-002928-41 Sponsor Protocol Number: Immunity_TBE Start Date*: 2013-01-14
    Sponsor Name:Med. Uni. Wien, Klinik für Innere I
    Full Title: Characterization of humoral and cellular immunity for tick-borne encephalitis (TBE) vaccination in allogeneic blood and marrow graft recipients: a pilot study
    Medical condition: Characterization of humoral and cellular immunity for tick-borne encephalitis (TBE) vaccination in allogeneic blood and marrow graft recipients: a pilot study Study group consists of patients 11...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2007-005503-17 Sponsor Protocol Number: 200710602 Start Date*: 2011-03-31
    Sponsor Name:Medizinische Hochschule Hannover
    Full Title: Randomized multicenter double-blind study of phase III in patients after kidney transplantation with an acute cellular rejection with a tubulointerstinal component in kidney transplant with histolo...
    Medical condition: It should be proved that additional treatment with Rituximab in patients with histologic proof of an acute cellular rejection with CD20+ lymphocytes is superior to a solitary therapy with Steroidbo...
    Disease: Version SOC Term Classification Code Term Level
    19.0 10021428 - Immune system disorders 10023439 Kidney transplant rejection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-001453-74 Sponsor Protocol Number: Version01.1. Start Date*: 2012-05-15
    Sponsor Name:Institute of Specific Prophylaxis and Tropical Medicine
    Full Title: Comparison of vaccination routes: subcutaneus versus intramuscular application of FSME-Immun®
    Medical condition: TBE vaccine (FSME-Immun®) is registered for intra-muscular application. Due to medical reasons (e.g. anticoagulant therapy, adipositas) intra-muscular application is not always possible. The aim o...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-005672-34 Sponsor Protocol Number: FSME_only_1.1 Start Date*: 2013-03-05
    Sponsor Name:Institut für Spezifische Prophylaxe
    Full Title: Application of FSME-Immun® in allergic patients
    Medical condition: Allergic patients have generally an altered immune-responsiveness (Th2 bias), and allergic individuals undergoing de-sensitization display an increased production of immune supressive cytokines. We...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2021-002088-23 Sponsor Protocol Number: DemiVac2021 Start Date*: 2021-05-05
    Sponsor Name:Sciensano
    Full Title: Covid-19: Safety and Immunogenicity of a Reduced Dose of the BioNTech/Pfizer BNT162b2 Vaccine in a Healthy Population (REDU-VAC)
    Medical condition: Healthy persons from age 18 till age 56
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-003303-18 Sponsor Protocol Number: rl.01.2013 Start Date*: Information not available in EudraCT
    Sponsor Name:Gedeon Richter Polska Sp. z o. o.
    Full Title: Clinical phase IV study assessing the efficacy and safety of the medicinal product Groprinosin in treatment of recurrent airway inflammation in children with impaired cellular immunity and diagnose...
    Medical condition: Recurrent airway inflammation in children with impaired cellular immunity.
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: PL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-001857-24 Sponsor Protocol Number: NI-0401-02 Start Date*: 2007-07-25
    Sponsor Name:NovImmune S.A.
    Full Title: A Phase IIa, open-label, dose-titration, multicentre study to assess the safety and preliminary efficacy of NI-0401 in patients with acute cellular renal allograftt rejection
    Medical condition: Acute cellular renal allograft rejection.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) GB (Completed) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-000570-19 Sponsor Protocol Number: TBE_obesity_1.1 Start Date*: 2014-07-11
    Sponsor Name:Institute of Specific Prophylaxis and Tropical Medicine
    Full Title: Applikation of FSME-IMMUN® in obese persons
    Medical condition: Studies have shown that obesity has a direct effect on the immune system and leads to immunosuppression, which leads to a susceptibility to infection. The aim of this study is to clarify if a modif...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-004406-42 Sponsor Protocol Number: FCO-TIM-2015-01 Start Date*: 2016-03-10
    Sponsor Name:FIBICO
    Full Title: CLINICAL TRIAL TO ASSEES THE NON-INFERIORITY OF THE SUSPENSION OF PROPHYLACTIC TREATMENT WITH VALGANCICLOVIR IN KIDNEY TRANSPLANT CMV-seropositive PATIENTS, WHO MANTEIN CD8+ CMV- CELLULAR IMMUNI...
    Medical condition: Kidney transplant cytomegalovirus-seropositive
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-001709-26 Sponsor Protocol Number: IMS012012 Start Date*: 2012-06-28
    Sponsor Name:Sevapharma,a.s.
    Full Title: Randomized, double-blind, placebo-controlled clinical trial of Immodin immunological efficacy in healthy adult volunteers.
    Medical condition: Immunological efficacy, in healthy volunteers
    Disease: Version SOC Term Classification Code Term Level
    14.1 10022891 - Investigations 10021422 Immune status LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-001775-20 Sponsor Protocol Number: CHDR1644 Start Date*: 2018-07-12
    Sponsor Name:Centre for Human Drug Research
    Full Title: Immunomonitoring of tacrolimus in healthy volunteers
    Medical condition: Immunesuppression
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2014-001023-80 Sponsor Protocol Number: 26 Start Date*: 2015-02-09
    Sponsor Name:Danish Head and Neck Cancer Group (DAHANCA)
    Full Title: DAHANCA 26. A phase II unblinded, randomized study of paclitaxel and capecitabine with or without cetuximab as first line treatment of recurrent or metastatic squamous cell head and neck cancer (HN...
    Medical condition: Recurrent or metastatic squamous cellular head and neck cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060121 Squamous cell carcinoma of head and neck PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-004891-33 Sponsor Protocol Number: T33/2021 Start Date*: 2022-04-13
    Sponsor Name:Turku University Hospital
    Full Title: COVID-19 vaccine induced immune response in patients with primary antibody deficiency
    Medical condition: COVID-19
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 25 01:16:44 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA